Streetbeat News

Stock Prices

LLY

PNT

Eli Lilly and Co (LLY) has agreed to acquire POINT Biopharma Global Inc (PNT) for $12.50 per share in cash, totaling approximately $1.4 billion. The purchase price represents a premium of about 87% to POINT's closing stock price on Oct. 2, 2023. PNT shares are up 84.35 at $12.32, and LLY stock is down 0.22% at $537.13 during the premarket session.

Portfolio Pulse from Vandana Singh

October 03, 2023 | 1:03 pm

ALB

Albemarle (NYSE:ALB) has received mixed analyst ratings in the last quarter, with 1 bullish, 6 somewhat bullish, 2 indifferent, and 2 somewhat bearish. The average 12-month price target for the company is $237.09, a decrease of 1.18% from the previous average of $239.91.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 1:00 pm

LTHM

Over the past 3 months, 4 analysts have published somewhat bullish opinions on Livent (NYSE:LTHM) stock. The average price target is $33.5, implying an upside from the current price of $17.2801. This average has decreased by 3.6% from the previous average price target of $34.75.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 1:00 pm

BWA

Over the past 3 months, 11 analysts have published their opinion on BorgWarner (NYSE:BWA) stock. The analysts have an average price target of $52.73 versus the current price of BorgWarner at $39.86, implying upside. This current average has decreased by 3.69% from the previous average price target of $54.75.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 1:00 pm

OTIS

In the last quarter, Otis Worldwide (NYSE:OTIS) received 6 indifferent analyst ratings. The company's average 12-month price target is $87.5, an increase of 1.98% from the previous average price target of $85.80.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 1:00 pm

RKT

Over the past 3 months, 6 analysts have published their opinion on Rocket Companies (NYSE:RKT) stock, all of them being indifferent. The company has an average price target of $9.92, which has increased by 14.42% over the past month.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 1:00 pm

ALXO

AZN

LLY

MRK

ALX Oncology Holdings Inc released interim Phase 2 data from its ASPEN-06 trial of evorpacept for HER2-positive gastric cancer, showing a 52% overall response rate. The results compare favorably to the efficacy reported for Eli Lilly's Cyramza. The trial included patients previously treated with AstraZeneca's Enhertu and Merck's Keytruda. ALXO plans to report the final analysis in Q2 2024 and initiate Phase 3 in late 2024. ALXO shares gained over 100% in premarket trading.

Portfolio Pulse from Vandana Singh

October 03, 2023 | 12:58 pm

SPY

The USA Redbook Year-over-Year (YoY) has reported a 3.5% increase, which is slightly lower than the previous 3.8%.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:56 pm

SPRC

SciSparc has been granted a European patent for its core technology, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:55 pm

VERY

iA Financial Group has announced its plans to acquire Vericity, leading to a rise in Vericity's stock prices.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:54 pm